| 0.84 0.19 (29.23%) | 01-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 10.29 | 1-year : | 12.02 |
| Resists | First : | 8.81 | Second : | 10.29 |
| Pivot price | 4.05  |
|||
| Supports | First : | 3.74 | Second : | 0.61 |
| MAs | MA(5) : | 7.71 |
MA(20) : | 3.23 |
| MA(100) : | 1.88 |
MA(250) : | 6.63 |
|
| MACD | MACD : | 1.8 |
Signal : | 1.2 |
| %K %D | K(14,3) : | 84.8 |
D(3) : | 87.3 |
| RSI | RSI(14): 79.3 |
|||
| 52-week | High : | 34.65 | Low : | 0.51 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SLRX ] has closed below upper band by 25.2%. Bollinger Bands are 694.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 7.69 - 7.74 | 7.74 - 7.78 |
| Low: | 6.3 - 6.35 | 6.35 - 6.38 |
| Close: | 7.51 - 7.6 | 7.6 - 7.66 |
Salarius Pharmaceuticals, Inc. is a clinical-stage biotechnology firm dedicated to advancing epigenetic-based cancer therapies. Its flagship investigational product, Seclidemstat (SP-2577), a small molecule inhibitor, is currently undergoing Phase I/II clinical evaluation. This compound is being developed to treat Ewing sarcoma and a range of advanced solid tumors. Another promising program involves SP-3164, a small molecule protein degrader designed to target both hematological and solid malignancies. The company has cultivated several key alliances. These include an exclusive licensing agreement with The University of Utah Research Foundation for the intellectual property associated with SP-2577 and related compounds. A collaboration with HLB Life Sciences grants rights for the comprehensive development, production, and commercialization of the drug in South Korea. Furthermore, Salarius partners with the Cancer Prevention and Research Institute of Texas (CPRIT) to accelerate product development activities. A research collaboration with the Cancer Epigenetics Institute at Fox Chase Cancer Center aims to uncover new indications and biomarkers for SP-2577. Corporate operations are managed from its headquarters in Houston, Texas.
Thu, 13 Nov 2025
Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger - GlobeNewswire
Tue, 09 Sep 2025
Document - SEC.gov
Thu, 14 Aug 2025
Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split - GlobeNewswire
Thu, 24 Apr 2025
Salarius Pharmaceuticals (SLRX) Stock Price, News & Analysis - Stock Titan
Fri, 21 Mar 2025
Salarius Pharmaceuticals, Inc. SEC 10-K Report - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 6 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 5.2 (%) |
| Shares Short | 185 (K) |
| Shares Short P.Month | 468 (K) |
| EPS | -24.24 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.5 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -70 % |
| Return on Equity (ttm) | -139.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.95 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -4 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -0.32 |
| PEG Ratio | 0 |
| Price to Book value | 1.68 |
| Price to Sales | 0 |
| Price to Cash Flow | -10.03 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|